Celgene International Sàrl (NASDAQ:CELG) today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either with a germinal center B-cell (GCB) or non-germinal center B-cell (non-GCB) phenotype.
Investigators retrospectively analysed pooled patient data from four academic centers around the world for differences in clinical outcomes among patients with either GCB or non-GCB large-cell lymphoma treated with salvage lenalidomide. The initial data set included 40 patients with relapsed or refractory DLBCL with 23 classified as GCB and 17 classified as non-GCB.
Results of the evaluation showed an overall response rate of 53% (9/17) for non-GCB patients versus 8.7% (2/23) for GCB patients>
The most common adverse events were consistent with those seen in other lymphoma studies of lenalidomide.
These data are from an investigational study. REVLIMID does not have marketing approval for the treatment of patients with previously treated DLBCL.
Celgene International Sàrl